Navigation Links
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Date:5/14/2008

ncer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding Poniard's (the "Company's") business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and the Company's Quarterly Report for the period ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any f
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Calif., April 30, 2015 Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... GAAP results: Revenue for the first quarter of 2015 ... the first quarter of 2014, and down $5.3 million ... First quarter 2015 net income as reported in ...
(Date:4/30/2015)...  Tandem Diabetes Care ® , Inc. (NASDAQ: TNDM ... ® and t:flex™ Insulin Pumps, today reported its financial ... In comparing the first quarter of 2015 to the ... to $12.3 million from $8.1 million , t:slim Pump ... "Our investment in resources to build the foundation ...
(Date:4/30/2015)... April 30, 2015  Cumberland Pharmaceuticals Inc. (NASDAQ: ... quarter 2015 financial results after the market closes on ... Internet webcast will be held on Thursday, May 7, ... results. To participate in the call, please ... callers).  A rebroadcast of the teleconference will be available ...
Breaking Medicine Technology:Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2
... Begins to Demonstrate Strategy to Expand NHL Marketplace ... Development Program -, BRITISH COLUMBIA, Canada, Sept. ... Bulletin Board: IXSBF;, http://www.ixsbio.com ), a drug development ... on its technology, Dynamic Cross,Linking (DXL(TM)), announced today ...
... Mymetics,Corporation (OTCBB: MYMX), a vaccine development company, ... results on non-human primates,previously immunized with the ... protection. The results significantly exceed the,Industry standard ... considered as a,promising vaccine as well as ...
Cached Medicine Technology:InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 3Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 2Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 3Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 4
(Date:5/3/2015)... 2015 Looking for a graduate ... impact your career? The Master of International Business, ... in multinational companies and for professionals seeking a ... global landscape, differences in culture, religion, government, and ... program develops the global competence and confidence needed ...
(Date:5/3/2015)... May 03, 2015 It is not too late ... Aneurysm Walk in Memory of Lissa Anne Been in Arnold, ... this great family-friendly event to honor her loving memory. It has ... , Just having turned 37, Lissa suffered a brain ... on August 24, 2012. This event is designed to serve as ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of ... Pro X. ProText Kinetic 2 features 40 animation ... Pro X . Easily create interactive text videos without ... ProText Kinetic 2. , Using ProText Kinetic is as easy ... Kinetic presets in the FCPX timeline. Playback the default ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured on NewsWatch ... the latest and coolest technology products available to consumers. ... NewsWatch, conducted the review and shared with viewers how ... is an important part of people’s lives – and ... royal treatment. Peachtree Audio does just that with high-end ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2
... are a bonus to everyone of us. The first ever ... shows a clear benefit. Angioplasty is a very widely used ... It involves inserting a small balloon into the blood vessel ... vessel apart. The problem is that in 20 per cent ...
... study, in the Journal of Pediatrics, has found a ... a condition that affects one in 500 newborns. ... second month of life, is a blockage of the ... to weight loss and dehydration. It is a common ...
... about siblings? If so, you might have a better memory for ... in a part of the brain called the corpus callosum, which ... family history of left-handedness, says study author Steven Christman. // ... that connects the two sides of our brain and is one ...
... Benckiser has deferred the launch of 'Disprin CV' (cardiovascular) ... painkiller 'Disprin Plus', the company's Regional Director , Mr. ... in the brand-name 'Disprin Plus' to 'Disprin Paracetamol'. Subsequent ... citing instances of concern from doctors and consumers regarding ...
... Risk factors such as insulin resistance and high blood pressure ... as age 14, say researchers according to a recent study. ... to an increased risk of heart attack, stroke and kidney ... related to other heart disease risk factors seen in adolescents, ...
... genetic abnormalities over time and new stem cell lines will ... key stem cell research committee of the National Research Council ... cell divide in a tissue culture it accumulates mutations. In ... cells are unspecialized cells that can become any cell type ...
Cached Medicine News:Health News:Cardiac diseases develop early 2Health News:A need for new stem cell lines 2
Medtronic Aortic Punches are intended for use by cardiac surgeons during coronary artery bypass grafting procedures to create an opening in the wall of the vessel. All punches are sterile and disposa...
... cardioverter defibrillators (ICDs) are designed to treat ... (SCD) due to arrhythmia. The size and ... is designed to facilitate ease of insertion ... 2 system incorporates Guidant's proprietary RHYTHM ID ...
... A-Scan 100 is a compact, portable ultrasound system ... a Windows Laptop or PC computer. The large ... using a single screen eliminating the need for ... , ,The automated features of the A-Scan 100 ...
... designed for fast and simple operation. Tone-assisted ... is aligned & measurements are recorded. The ... use in the IOL calculation. The AL-100 ... accuracy of 0.1mm and a resolution of ...
Medicine Products: